|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | G01N 33/53 | |
| G01N 33/68 | |||
| A61K 39/395 | |||
| A61P 35/00 | |||
| C12Q 1/68 | |||
| C07K 14/47 | |||
| G01N 33/50 | |||
| C07K 7/06 |
| (11) | Number of the document | 2569633 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11781409.5 |
| Date of filing the European patent application | 2011-05-16 | |
| (97) | Date of publication of the European application | 2013-03-20 |
| (45) | Date of publication and mention of the grant of the patent | 2016-02-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/036665 |
| Date | 2011-05-16 |
| (87) | Number | WO 2011/143656 |
| Date | 2011-11-17 |
| (30) | Number | Date | Country code |
| 334866 P | 2010-05-14 | US |
| (72) |
HACOHEN, Nir, US
WU, Catherine, US
|
| (73) |
The General Hospital Corporation,
55 Fruit Street, Boston, MA 02114,
US
Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215, US |
| (54) | COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS |
| COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS |